Recent News

• 04.01.2025 - Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.01.2025 - Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.31.2025 - Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
• 03.31.2025 - Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
• 03.25.2025 - Biomea Fusion Announces Leadership Transition
• 03.25.2025 - Biomea Fusion Announces Leadership Transition
• 03.24.2025 - Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
• 03.24.2025 - Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
• 03.19.2025 - Citi - KOL Call to Discuss Menin Inhibitors for Diabetes – with Dr. Ralph DeFronzo
• 03.19.2025 - Citi - KOL Call to Discuss Menin Inhibitors for Diabetes – with Dr. Ralph DeFronzo

Recent Filings

• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - 8-K Current report
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report